23948sdkhjf
Log in or create to bookmark articles
Get access to all content on Life Science Focus
No commitment or card information required
Applies to personal subscription only.
Contact us for a enterprise solution.
Advertisement
Advertisement

Schizophrenia drug shows promise in Alzheimer’s psychosis

A schizophrenia drug from Bristol Myers Squibb has shown promising results against psychotic symptoms in patients with Alzheimer's disease in two Phase 3 trials.
Advertisement

Cobenfy, a combination of xanomeline and trospium chloride, was approved in the US in 2024 for the treatment of schizophrenia. The drug is now being investigated in several Phase 3 trials as a treatment for patients with psychosis associated with Alzheimer's disease. One trial is assessing the initial treatment response, while another primarily examines the long-term safety and tolerability of the treatment.

Advertisement Advertisement
BREAKING
{{ article.headline }}
0.063|